Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users

This analysis (n=66,807) found people with type 2 diabetes on metformin plus sulfonylurea had the highest risk of all endpoints aside from hypoglycaemia. The lowest risk of major adverse cardiovascular events was seen for those on a GLP-1 agonist containing regimen.


Diabetes Care